Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Serina Therapeutics's Enterprise Value is $21.55 Mil.
Serina Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $1.49 Mil. Therefore, Serina Therapeutics's EV-to-EBIT ratio for today is 14.45.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Serina Therapeutics's Enterprise Value is $21.55 Mil.
Serina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $1.57 Mil. Therefore, Serina Therapeutics's EV-to-EBITDA ratio for today is 13.74.
Serina Therapeutics Enterprise Value Historical Data
The historical data trend for Serina Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Serina Therapeutics Enterprise Value Chart
Serina Therapeutics Annual Data
Trend
Dec21
Dec22
Enterprise Value
-
-
Serina Therapeutics Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Enterprise Value
-
-
-
-
Competitive Comparison of Serina Therapeutics's Enterprise Value
For the Biotechnology subindustry, Serina Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's Enterprise Value falls into.
Serina Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Serina Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Serina Therapeutics (AMEX:SER) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Serina Therapeutics's current Enterprise Value is $21.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Serina Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $1.49 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Serina Therapeutics's current Enterprise Value is $21.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Serina Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $1.57 Mil.
Serina Therapeutics's current Enterprise Value is $21.55 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Serina Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Serina Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Serina Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Serina Therapeutics (Serina Therapeutics) Business Description
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SER has been successfully added to your